PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
153.33%
Growth of 153.33% versus flat Biotechnology revenue. Walter Schloss would verify growth quality.
-27.15%
Cost reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive advantage potential.
73.30%
Growth of 73.30% versus flat Biotechnology gross profit. Walter Schloss would verify quality.
89.46%
Margin change of 89.46% versus flat Biotechnology margins. Walter Schloss would verify quality.
8.30%
R&D change of 8.30% versus flat Biotechnology spending. Walter Schloss would verify adequacy.
28.80%
G&A change of 28.80% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.70%
Operating expenses growth exceeding 1.5x Biotechnology median of 3.93%. Jim Chanos would check for waste.
14.70%
Total costs growth exceeding 1.5x Biotechnology median of 3.89%. Jim Chanos would check for waste.
-100.00%
Interest expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-27.15%
D&A reduction while Biotechnology median is 0.46%. Seth Klarman would investigate efficiency.
-16.20%
EBITDA decline while Biotechnology median is -1.17%. Seth Klarman would investigate causes.
54.13%
Margin change of 54.13% versus flat Biotechnology. Walter Schloss would verify quality.
-15.23%
Operating income decline while Biotechnology median is -3.83%. Seth Klarman would investigate causes.
54.52%
Margin change of 54.52% versus flat Biotechnology. Walter Schloss would verify quality.
98.15%
Other expenses growth exceeding 1.5x Biotechnology median of 14.02%. Jim Chanos would check for issues.
-12.38%
Pre-tax income decline while Biotechnology median is -1.07%. Seth Klarman would investigate causes.
55.64%
Margin change of 55.64% versus flat Biotechnology. Walter Schloss would verify quality.
-98.15%
Tax expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-9.33%
Net income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
56.84%
Margin change of 56.84% versus flat Biotechnology. Walter Schloss would verify quality.
-5.41%
EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-8.33%
Diluted EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
2.98%
Share count reduction below 50% of Biotechnology median of 0.10%. Jim Chanos would check for issues.
2.03%
Diluted share reduction below 50% of Biotechnology median of 0.08%. Jim Chanos would check for issues.